Mechanisms of Loss of Response to Adalimumab in Crohn's Disease

被引：0
|
作者：
Wolf, Douglas C.
Hauenstein, Scott
Lockton, Steven
Singh, Sharat
机构：
来源：
GASTROENTEROLOGY | 2013年 / 144卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S775 / S775
页数：1
相关论文
共 50 条
  • [1] Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease
    Bauer, Christina M.
    Younis, Adam
    Herfarth, Hans
    Barnes, Edward L.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (02) : E5 - E5
  • [2] Response to the Letter to the Editor: "Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease"
    Casanova, Maria Jose
    Chaparro, Maria
    Gisbert, Javier P.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (02) : E6 - E6
  • [3] Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab
    Peeters, H.
    Louis, E.
    Baert, F.
    Dewit, O.
    Coche, J. C.
    Ferrante, M.
    Lambrecht, G.
    Colard, A.
    Van Gossum, A.
    Bossuyt, P.
    Moreels, T.
    Vander Cruyssen, B.
    Gils, A.
    De Vos, M.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2018, 81 (01) : 15 - 21
  • [4] Efficacy of switching to infliximab in Crohn's disease patients with loss of response to adalimumab
    Peeters, H.
    Louis, E.
    Baert, F.
    Dewit, O.
    Coche, J. -C.
    Ferrante, M.
    Lambrecht, G.
    Colard, A.
    Van Gossum, A.
    Bossuyt, P.
    Moreels, T.
    De Vos, M.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S274 - S274
  • [5] An open label study of adalimumab in Crohn's disease patients with a loss of response to infliximab
    Anwar, Malik
    O'Sullivan, Maria
    Ryan, Barbara
    Breslin, Niall
    O'Connor, Humphrey
    O'Morain, Colm
    GASTROENTEROLOGY, 2006, 130 (04) : A662 - A662
  • [6] Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease
    Ma, C.
    Huang, V.
    Fedorak, D. K.
    Kroeker, K. I.
    Dieleman, L. A.
    Halloran, B. P.
    Fedorak, R. N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (09) : 1044 - 1055
  • [7] Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
    Billioud, Vincent
    Sandborn, William J.
    Peyrin-Biroulet, Laurent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (04): : 674 - 684
  • [8] Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab
    Duveau, Nicolas
    Nachury, Maria
    Gerard, Romain
    Branche, Julien
    Maunoury, Vincent
    Boualit, Medina
    Wils, Pauline
    Desreumaux, Pierre
    Pariente, Benjamin
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (02) : 163 - 169
  • [9] Adalimumab Dose Escalation Is Effective and Well Tolerated in Crohn's Disease Patients With Secondary Loss of Response to Adalimumab
    Duveau, Nicolas
    Nachury, Maria
    Boualit, Medina
    Gerard, Romain
    Branche, Julien
    Maunoury, Vincent
    Desreumaux, Pierre
    Pariente, Benjamin
    GASTROENTEROLOGY, 2016, 150 (04) : S813 - S814
  • [10] Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab
    Duveau, N.
    Nachury, M.
    Boualit, M.
    Gerard, R.
    Branche, J.
    Maunoury, V.
    Desreumaux, P.
    Pariente, B.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S320 - S320
12345